Drug company trade body suggests concerns around intellectual property will push R&D investment elsewhere
Plans to change EU rules on drug development would be “extremely damaging” to the bloc’s pharmaceutical industry, according to a trade body.
The European Commission is expected to publish its plans in the coming weeks, with expressed aims that include supporting innovation and ensuring medicines are accessible and affordable.